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Evidence suggests that 24.5%–46.7% (mean 31%) of patients with Parkinson’s disease 
experience an anxiety disorder, a much higher prevalence than in controls. Anxiety does not 
appear to be a consequence of diagnosis or the motoric symptoms of the disorder and can 
manifest as Generalised Anxiety Disorder, phobias or panic attacks. At present, the neural 
underpinnings of anxiety disorders in Parkinson’s disease is unknown. Here, we make the novel 
proposal that the superior colliculus (SC), one component of a rapid, reflexive threat detection 
system in the brain, consisting of the colliculus, pulvinar and amygdala, becomes hyper-
responsive to sensory stimuli following dopamine denervation of the striatum in Parkinson’s 
disease. This in turn leads to heightened responses to existing threat-related stimuli (giving rise 
to phobias and panic attacks), and heightened responses to anticipated threats (giving rise to 
Generalised Anxiety Disorder). This proposal is supported by a range of evidence, in particular 
elevated visual responses in the SC in an animal model of Parkinson’s disease and in 
Parkinson’s disease itself. Also facilitated saccadic eye movements (prosaccades, express 
saccades and fixational saccades) and increased distractibility in Parkinson’s disease, both of 
which involve the SC. Identifying one potential locus of change in the brain in Parkinson’s 
disease relevant to anxiety gives a potential target for interventions to combat a non-motor 






Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of 
dopamine-containing neurons primarily within the substantia nigra pars compacta of the 
midbrain [1,2]. The disease is typically characterised by a classical syndrome of bradykinesia, 
tremor, and muscular rigidity [3,4]. Research has tended to focus on these motor symptoms of 
Parkinson’s disease, however a number of non-motor symptoms are now also recognised to be 
part of the disorder [5]. The most common non-motor symptoms include anxiety, depression, 
psychosis, sleep problems, impulse control disorders and sensory changes [5-7]. 
 
Anxiety in Parkinson’s disease 
In terms of anxiety, a recent meta-analysis [8] suggests that 24.5%– 46.7% (mean 31%) of 
Parkinson’s patients experience an anxiety disorder, meeting the criteria of the Diagnostic and 
Statistical Manual of the American Psychiatric Association, or accepted cut off points on 
validated anxiety scales. Of the disorders present, Generalised Anxiety Disorder is the most 
frequently reported (14.1%), then social phobia (13.8%) and clinically relevant anxiety not 
meeting criteria for any specific anxiety diagnoses (anxiety NOS, 13.3%). Agoraphobia (8.6%), 
other phobias (13.0%) and panic disorder (6.8%) are also present and a number of patients 
(31%) exhibit more than one anxiety disorder. These prevalence rates far exceed those of 
similarly aged individuals without Parkinson’s disease. For example, the overall prevalence of 
anxiety disorders has been reported to be 5.5% in people over the age of 65 years (compared 
with 7.3% in subjects of all ages) in the United States [9], and 3.5-5.5% (6.5% for all ages) in 
a Canadian study [10]. Unsurprisingly, anxiety has a significant negative impact on quality of 
life in people with Parkinson’s disease [11]. 
Anxiety frequently develops before the motor symptoms [e.g. 12], suggesting that 
anxiety may not simply represent a psychological response to the difficulties of adapting to the 
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diagnosis of Parkinson’s disease, or the motor consequences of the disorder but may instead 
relate to the neurobiological underpinnings of the disorder itself. That said, there is evidence 
of a relationship between anxiety in Parkinson’s disease and the medication given to treat the 
motor symptoms, and indeed it has been claimed that antiparkinsonian drugs may have a role 
in the pathogenesis of the anxiety in the disorder [13]. For example, Lang [14] reported that 
5/26 late-stage Parkinson’s patients developed anxiety symptoms de novo when pergolide (a 
dopamine agonist) was added to their treatment. Likewise, Vasquesz et al. [15] found a clear 
cut relationship of panic disorder with higher doses of levodopa (but not other drugs). 
Although not universally the case, anxiety symptoms appear to be more strongly 
associated with ‘off’ periods rather than ‘on’ periods of the medication cycle [16]. In a double 
blind placebo controlled trial, Maricle et al. [17] found that anxiety levels fell during a levodopa 
infusion, followed by a precipitous increase in anxiety over the next 2.5 hours. Racette et al. 
[18] found off-period anxiety in 62 out of 1,063 early-stage Parkinson’s patients, and in a recent 
systematic review, van der Velden et al. [19] report that 81.8% to 88% of fluctuations in anxiety 
are associated with off periods, with the remaining 12% to 18.2% related to on periods or 
fluctuating independently of the motor state. Vasquez et al. [15] go so far as to suggest that 
anxiety (in their case panic attacks) could be considered part of an abstinence syndrome from 
levodopa. 
 
Anxiety and its neurobiological basis 
If, as has been suggested, anxiety in Parkinson’s disease does not represent a response to the 
difficulties of adapting to the diagnosis of Parkinson’s disease, or the motor consequences of 
the disorder, but instead relates to the neurobiological underpinnings of the disorder [12], a 
question arises as to what aspect(s) of the pathological process that give rise to Parkinson’s 
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disease are involved in generating anxiety in the condition? – A question that is currently 
unanswered. Our main hypothesis (see later) is directly related to that. However, to 
contextualise that hypothesis more fully, we must first consider the nature of anxiety and the 
neurobiological basis (or bases) of anxiety itself. With respect to anxiety, most definitions agree 
that anxiety is related to both fear and to threat. According to the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5; [20]), “Fear is the emotional response to 
real or perceived imminent threat, whereas anxiety is anticipation of future threat” or in the 
case of phobias, an “excessive or unreasonable” response to perceived threat (see also [21-23]). 
Fear and anxiety are normal reactions to real or imagined threat and are not themselves 
pathological. However, when fear and anxiety are recurrent and persistent, and interfere with 
the quality of life, then an anxiety disorder exists [24].  
Although the types of anxiety reported in Parkinson’s disease - Generalised Anxiety 
Disorder, phobias and panic disorder - are phenomenologically different and have different 
triggers, there are clear, unifying relationships between them. Phobias normally involve an 
initial traumatic learning experience, which becomes associated by classical conditioning with 
the object of the phobia [24]. In contrast to the external signal that triggers a phobic response, 
it has been proposed that panic relates to internal rather than external signals [25], and may 
represent the inappropriate activation of an alarm system more usually associated with 
separation in childhood [26]. Once an initial panic attack has taken place, internal stimuli 
around at the time will become conditioned to the panic attack (unconditioned stimulus), 
triggering future attacks if those stimuli are encountered again via classical conditioning [24]. 
The links to classical conditioning and stimulus-related triggers are not the only features that 
unite these anxiety disorders. Panic attacks and phobias are often co-morbid [e.g. 27]. Indeed, 
when the physiological responses during panic attacks and the exposure to feared objects in 
phobias are compared, the similarities are more apparent than the differences, and it has been 
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argued that they represent the activation of one and the same underlying anxiety response [28]. 
LeDoux [24] adds Generalised Anxiety Disorder to phobias and panic disorder, concluding 
that all three probably relate to the same underlying brain system. 
So, the question is – what is that brain system? Given the clear relationship between 
anxiety and threat, it may be useful to look firstly at the brain system(s) responsible for threat 
detection. The amygdala is critically involved in an organism’s response to sources of danger, 
as evidenced by a large number of neurobiological and neuroimaging studies [e.g. 29-34]. To 
be able to respond to danger quickly and reflexively, humans and infra-human mammals have 
evolved a direct pathway to the amygdala that bypasses the primary sensory cortices. 
Functional evidence for the existence of such a pathway comes from patients with striate cortex 
lesions, who are unable to consciously experience a visual stimulus presented to their blind 
visual field – ‘blindsight’. In response to fear-related stimuli, blindsight patients show 
enhanced amygdala activation which covaries with activity in the superior colliculus and 
pulvinar [35]. 
The superior colliculus (SC) is a visual (superficial layers) and multimodal (deep layers) 
sensory structure in the midbrain which is intimately linked to eye movements and attentional 
focus [e.g. 36]. Although an evolutionarily ancient subcortical structure [37], evidence suggests 
that the structure possesses relatively sophisticated processing abilities, for example in primates 
for the detection of some high level visual features such as faces [38,39], a source of potential 
threat. Coupled with the finding that disinhibition of the SC in monkeys elicits defensive 
behaviour [40], and bilateral lesions of the SC induce impaired recognition of a threatening 
stimulus (rubber snake model) in infant monkeys [41], the colliculus appears to be the visual 
‘front end’ of a threat detection and response system. This is reinforced by the observation that 
activating the colliculus elicits cardiovascular alerting (pressor) responses [42] and cells in the 
colliculus exhibit vigorous response to looming stimuli [43]. Collicular responses to potentially 
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threatening stimuli are also found in the human SC. For example, fearful (vs neutral) faces 
produce activation in the human colliculus [44] as do snake-related stimuli [45]. 
The superior colliculus projects to the pulvinar [46], where some neurons in the primate 
also preferentially respond to snakes and faces, in particular angry faces [47]. Likewise, fearful 
(vs neutral) faces and snake-related stimuli also produce activation in the human pulvinar 
[44,45]. Given that the pulvinar projects to the amygdala [48], it has been suggested that the 
SC, pulvinar and amygdala constitute a functional network concerned with the non-conscious 
perception threat-related facial stimuli [44,49,50]. The collicular pathway appears to provide 
rapid analysis of the emotional attributes of stimuli, offering a ‘low road’ of affective visual 
stimuli to the amygdala without routing through the cortex [51]. Fearful (threatening) images 
passing through the colliculus and pulvinar would elicit fast amygdalar activation, which, in 
turn, would trigger autonomic and behavioural responses [24]. Following threatening and 
traumatic events, amygdala responsivity and associated vigilance may be abnormally 
enhanced, as observed in disorders such as phobias [52], leading to an anxiety disorder. By the 
same token, other processes which enhance activity in this network may also similarly lead to 
an anxiety disorder. It is this possibility that leads us to our central hypothesis. 
 
Hypothesis 
In Parkinson’s disease, the SC becomes hyper-responsive to sensory stimuli, leading to 
abnormally intense responses to threatening stimuli that are currently experienced (giving rise 
to phobias and panic), and to higher levels of baseline activity that drive the threat circuit in 





Collicular function and dysfunction in Parkinson’s disease 
We have previously reported [53] that visual responses in the intermediate and deep layers of 
the rat SC are facilitated following partial or total lesions of dopaminergic neurons in the 
substantia nigra pars compacta (once the colliculus is disinhibited). Responses are faster, larger 
in amplitude and last longer compared to those in control rats. Baseline activity in the absence 
of visual stimulation is also elevated. More recently, we have extended this finding to de novo, 
drug naïve Parkinson’s patients [54]. Using blood oxygen level-dependent (BOLD) functional 
magnetic resonance imaging, we measured visual responses in the SC to achromatic 
checkerboards with luminance contrasts varying from 1% to 9%. Compared to controls, 
Parkinson’s patients exhibited a larger BOLD response at low contrast, which saturated at high 
contrast (Figure 1). This effect was still present 2 and 6 months after the start of anti-
Parkinsonian medication. 
Elevating collicular activity in the mouse increases panic-related behaviour during the 
confrontation with a snake [55]. While we are unaware of any studies that have deliberately 
tested Parkinson’s patients for their responses to snakes or other biologically relevant threats, 
Parkinson’s patients often ‘freeze’ as they approach a doorway or an object in their path 
[56,57]. Under natural conditions, abrupt freezing is a normal response to rapid visual detection 
of threatening stimuli, including peripheral and looming objects and dangerous objects in one’s 
path [58]. The SC-pulvinar visual system in humans is responsive to such stimuli (e.g. looming 
objects; [59]). In Parkinson’s disease, collicular hyper-responsiveness may lead mildly 
threatening stimuli like those signalling enclosure (e.g. a doorway) to elicit responses 
appropriate for a more significant threat (freezing) [58].  
Further evidence for collicular hyper-responsiveness in Parkinson’s disease comes from 
studies of saccadic eye movements. Visually triggered saccades (sometimes called reflexive or 
automatic saccades) are initiated by the sudden appearance of a visual stimulus and involve the 
9 
 
SC [60,61]. In prosaccade tasks where subjects have to make such saccades to visual targets, 
Parkinson’s patients have been described as ‘hyper-reflexive’ [62-64]. Hence, patients have 
been reported to be significantly faster in their saccadic reaction times than controls, without 
affecting accuracy [63,65,66]. This effect is present when the patients are medicated [66] or 
unmedicated [63,65]. Patients have also been reported to benefit more than controls from the 
effects of cues as to the direction of the upcoming saccadic target [62,64], and to make more 
express (short latency) saccades [65,67], and fixational saccades [68], saccadic types in which 
the colliculus plays a particular role [69,70]. 
As well as playing a role in eye movement generation, the SC also has a particular role 
to play in the detection of unexpected phasic stimuli [36]; i.e., the colliculus not only organises 
responses to sensory stimuli – for example saccades – but is also exclusively involved in 
detecting certain classes of stimuli. Consistent with this role, work in a range of species has 
shown that collicular lesions lead to a decrease in ‘distractibility’ (rat [71]; monkey [72]). In 
humans, disconnecting the colliculus from the controlling influence of the prefrontal cortex 
leads to an increase in distractibility [73], suggesting that the structure’s function of detecting 
unexpected (distracting) stimuli is preserved in humans. Parkinson’s patients have been 
reported to make more saccades to distracter stimuli and non-target stimuli than controls 
[64,74], again suggesting that the SC is hyper-responsive to sensory stimuli in Parkinson’s 
disease.  
Distractibility in the aforementioned studies in rats, monkeys and humans concerns the 
detection of non-threatening stimuli, to which the agent would normally make an orienting 
response. Likewise, visually triggered reflexive saccades initiated by the sudden appearance of 
a visual stimulus orient the eyes towards the stimulus. However, the colliculus is considered to 
have a dual functional role, where it not only organises orienting responses, but also organises 
escape responses to threat [36,40,75]. Hyper-reflexivity and increased distractibility in 
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Parkinson’s disease coupled with the hypothesised exaggeration in the response to threat 
suggests that sensory hyper-responsivity in Parkinson’s disease sensitises both aspects of 
collicular function. 
 
Conclusion and next steps 
Evidence reviewed above suggests that in Parkinson’s disease, subsequent to the loss of 
dopamine from the striatum, the SC becomes hyper-responsive to sensory stimuli, as evidenced 
by elevated visual responses (and baseline activity) in the rat SC following lesions of the 
nigrostriatal dopamine system [53], increased collicular activation by low contrast stimuli in 
Parkinson’s patients [54], as well as hyper-reflexivity in the generation of reflexive saccades 
to visual targets [e.g. 65], increased levels of express saccades/fixational saccades [e.g. 67,68], 
and increased distractibility to unexpected visual stimuli [e.g. 74]. How striatal dopamine 
denervation translates into collicular hyper-responsivity has yet to be empirically determined. 
However, the striatum projects to the SNr, which then sends a GABAergic projection to the 
SC [76,77], and hence there may be some alteration in the ongoing regulation of the SC by this 
inhibitory pathway. 
Given that the SC, pulvinar and amygdala have been proposed to constitute a functional 
network concerned with the non-conscious perception threat-related stimuli [e.g. 49], and 
anxiety’s close relationship with threat (anxiety being the anticipation of future threat, or a 
disproportionate response to existing threat), an enhanced responsivity in a circuit mediating 
threat responses following elevated responding in the SC could be sufficient to generate 
anxiety. That would manifest as phobic/panic attacks to sensory triggers and/or generalised, 
free-floating anxiety in the absence of explicit triggers caused by elevated baseline activity in 
the threat circuit. A natural question however is why - since our imaging data [54] and the 
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saccadic hyper-reflexivity findings [e.g. 65,66] suggest that the colliculus is hyper-responsive 
in both medicated and unmedicated patients with Parkinson’s disease – is anxiety worse in the 
unmedicated state [e.g. 15]? The answer may lie at the level of the amygdala. Although 
evidence is scant, resting activity levels in the amygdala have been reported to be higher in 
some Parkinson’s patients off medication ([78]; however, see [79]), whilst amygdala activity 
appears to be suppressed in the medicated state (amygdala-derived event-related potentials to 
fearful faces are absent; [80]). Anti-parkinsonian medication may thus be able to turn off or 
turn down responses in a critical part of the threat detection system, thus blocking the effects 
of elevated afferent input. 
In conclusion, we have reviewed considerable evidence in support of the contention that 
enhanced activity in a circuit mediating threat responses following elevated sensory 
responsivity in the SC could generate anxiety on Parkinson’s disease. However, the hypothesis 
still lacks a direct test. Amongst the possible predictions of the collicular hypothesis that could 
be tested is whether the SC responds vigorously to threatening stimuli in Parkinson’s patients. 
A number of threat paradigms exist that could be used to test that possibility, for example 
shooting paradigms [e.g. 81], and the elevated (virtual) plank [82]. More work is also required 
to elucidate the status of the amygdala in Parkinson’s disease, both in medicated and 
unmedicated patients, using paradigms focusing on resting state activity and responses to 
threat. Confirming enhanced amygdala activity in unmedicated Parkinson’s patients and 
suppressed amygdala activity in medicated Parkinson’s patients would have important 
theoretical consequences. Evidence at the moment is both scant and somewhat contradictory. 
Finally, what implications does our hypothesis that anxiety in Parkinson’s disease arises 
(at least in part) from a hyper-responsive SC, the sensory front-end of the unconscious threat 
detection system, have for therapy? Evidence suggests that the SC receives extensive 
noradrenergic [83] and serotonergic [84] innervation. Noradrenaline and 5-HT have 
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predominantly inhibitory actions on collicular visual responses [85,86]. Hence it may be 
possible to turn down collicular responsiveness by the use of drugs targeting noradrenaline and 
5-HT-mediated transmission in the SC. In that regard it is interesting that tricyclic 
antidepressants (which affect noradrenaline and 5-HT) and Selective Serotonin Uptake 
Inhibitors are both effective against anxiety in Parkinson’s disease [e.g. 87]. 
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FIGURE 1: Effects of increasing luminance contrast and dopaminergic treatment on collicular 
responses to achromatic checkerboard stimuli at varying levels of luminance contrast in 
patients with Parkinson’s disease. Left panel: Average variations (± standard error of the mean 
[SEM]) in the blood oxygenation level–dependent (BOLD) signal in the superior colliculi 
according to luminance contrast changes (versus fixation; right and left hemispheres combined) 
in de novo, drug naïve patients with Parkinson’s disease (N = 22) and matched controls. Right 
panel: Average variations (± SEM) of the BOLD signal in the superior colliculi according to 
luminance contrast changes (versus fixation; right and left hemispheres combined) in 
Parkinson’s patients (N = 8) at 2 and 6 months after starting levodopa or dopamine agonist 
treatment, and controls. Modified from [54] with permission from John Wiley & Sons. 
 
Experimental details: Twenty-three de novo Parkinson’s disease patients (age = 57.27 ± 2.24 
years; 17 males; one female patient did not complete the scan) and 23 age-matched healthy 
controls (age = 55.54 ± 2.01 years; 13 males) took part. All patients had received a recent 
diagnosis (≤1 year) of Parkinson’s disease, and were not taking antiparkinsonian treatment at 
the time of the initial scan. MRI acquisitions were performed using a whole-body 3-T MRI 
scanner (Achieva; Philips Medical Systems, Best, the Netherlands) equipped with a 32-channel 
SENSE head coil. Participants were presented with a series of achromatic checkerboards with 
4 levels of luminance contrast (1%, 3%, 5%, and 9%), flashing at a frequency of 4 Hz on a grey 
background, presented to each hemifield in turn across sessions. For functional scans, a 
standard gradient echo planar imaging sequence was used (repetition time = 2,000 ms; echo 
time = 30 ms, flip angle = 80°, matrix size = 128×144, field of view = 192×216). High-
resolution structural images were also acquired and used for manual delineation of the SC and 
other regions of interest. Parkinson’s disease patients who had started L-dopa or dopamine 
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agonist treatment after completing the first scan (N=8), were scanned a second and a third time 
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